Radiation Therapy for Oropharyngeal Cancers

Phase-Based Progress Estimates
University of Michigan Hospital, Ann Arbor, MIOropharyngeal CancersRadiation Therapy - Radiation
All Sexes
What conditions do you have?

Study Summary

This trial will use PET-CT scans to see if a patient's cancer has shrunk enough before and during radiation treatment to lower the amount of radiation given.

Eligible Conditions
  • Oropharyngeal Cancers

Treatment Effectiveness

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: 2 Years

1 Year
The percentage of patients with Local Regional Recurrence (LRR) of disease
2 Years
The proportion of patients alive
The proportion of patients who progress in any location
Month 24
Incidence of Toxicity

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

2 Treatment Groups

Standard Treatment
1 of 2
De-escalation Treatment
1 of 2

Active Control

Experimental Treatment

75 Total Participants · 2 Treatment Groups

Primary Treatment: Radiation Therapy · No Placebo Group · Phase 2

De-escalation TreatmentExperimental Group · 3 Interventions: Paclitaxel, Carboplatin, Radiation Therapy · Intervention Types: Drug, Drug, Radiation
Standard TreatmentActiveComparator Group · 3 Interventions: Paclitaxel, Carboplatin, Radiation Therapy · Intervention Types: Drug, Drug, Radiation
First Studied
Drug Approval Stage
How many patients have taken this drug
FDA approved
FDA approved
Radiation Therapy
Completed Phase 3

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 2 years

Who is running the clinical trial?

VA Ann Arbor Healthcare SystemFED
16 Previous Clinical Trials
4,936 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,151 Previous Clinical Trials
41,162,705 Total Patients Enrolled
16 Trials studying Oropharyngeal Cancers
1,754 Patients Enrolled for Oropharyngeal Cancers
University of Michigan Rogel Cancer CenterLead Sponsor
269 Previous Clinical Trials
18,060 Total Patients Enrolled
Michelle Mierzwa, M.D.Principal InvestigatorUniversity of Michigan Rogel Cancer Center
3 Previous Clinical Trials
137 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 3 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Frequently Asked Questions

To what extent is this trial impacting the treatment of individuals?

"Affirmative. Clinicaltrials.gov conveys that this research project, which was first uploaded on May 21st 2018, is actively enrolling individuals. Approximately 75 people need to be recruited from 2 different medical facilities." - Anonymous Online Contributor

Unverified Answer

What other research has been conducted exploring the application of Radiation Therapy?

"Presently, 1174 trials are ongoing that examine Radiation Therapy. Of those active studies, 332 have reached Phase 3 and encompass 66513 different sites around the world; many of these locales being concentrated in Shanghai." - Anonymous Online Contributor

Unverified Answer

Are there still openings for prospective participants in this clinical research?

"This research project is actively recruiting new participants, per the information found on clinicaltrials.gov. This trial was posted in May 2018 and last updated in February 2022." - Anonymous Online Contributor

Unverified Answer

Has the US Food & Drug Administration sanctioned radiation therapy?

"The safety of Radiation Therapy was rated a 2 due to the Phase 2 trial; although there is data confirming its security, no research has yet confirmed efficacy." - Anonymous Online Contributor

Unverified Answer

What types of maladies are typically remedied through the use of Radiation Therapy?

"Radiation Therapy is a common treatment option for melanoma and can be used in the management of other malignancies such as neoplasm metastasis, lymphoma, non-Hodgkin’s disease and advanced sarcoma." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.